Skip to main content
Entera Bio Ltd. logo

Entera Bio Ltd. — Investor Relations & Filings

Ticker · ENTX ISIN · IL0011429839 LEI · 549300C3XPVV86UK2O23 US Manufacturing
Filings indexed 373 across all filing types
Latest filing 2026-06-03 Proxy Solicitation & In…
Country IL Israel
Listing US ENTX

About Entera Bio Ltd.

https://enterabio.com/

Entera Bio Ltd. is a clinical-stage company developing orally delivered peptide and protein replacement therapies. The company leverages its proprietary N-Tab™ technology platform, which is designed to stabilize peptides in the gastrointestinal tract and promote their absorption into the bloodstream, offering a tablet-based alternative to injections. Its development pipeline targets significant unmet medical needs. Key programs include EB613, an oral teriparatide (PTH(1-34)) for postmenopausal women with high-risk osteoporosis, and EB612 for patients with hypoparathyroidism. Other programs include an oral oxyntomodulin for obesity and an oral GLP-2 peptide for rare malabsorption conditions such as short bowel syndrome.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement
2026-06-03 English
ARS
Annual Report
2026-06-03 English
DEF 14A
Proxy Solicitation & Information Statement
2026-06-03 English
424B3
Regulatory Filings Classification · 75% confidence The document is an SEC Form 424B3 prospectus, clearly a regulatory registration statement for the resale of existing shares by selling shareholders under a shelf registration. It is not a full financial report (10-K, IR), an earnings release, proxy statement, call transcript, or a dividend notice. It also does not involve the company raising primary capital (it’s a secondary offering), so it does not fit “Capital/Financing Update” or “Share Issue/Capital Change.” The filing is therefore best categorized under the fallback “Regulatory Filings” (RNS).
2026-05-15 English
10-Q - Entera Bio Ltd. (0001638097) (Filer)
Interim / Quarterly Report
2026-05-08 English
Stromnetz unter Druck, Milliarden flieen und ein kaum bekannter Micro-Cap konnte profitieren (OTCQB: DUKRD)
Regulatory Filings Classification · 40% confidence The document is a corporate news/press release distributed via EQS News, containing marketing content and disclaimers, rather than an official financial report, management change notice, earnings release, or other specific statutory filing. It does not present financial results, governance details, or any M&A, insider transactions, or dividend notice. As it does not fit any specialized category, it falls into the fallback “Regulatory Filings” category (RNS).
2026-03-25 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.